ストックスクリーナーアプリを入手
4.86
3.76%
-0.19
アフターアワーズ：
4.86
前日終値:
$5.05
開ける：
$5.03
24時間の取引高:
252.41K
Relative Volume:
1.00
時価総額：
$182.30M
収益：
$147.12M
当期純損益:
$-33.88M
株価収益率:
-10.11
EPS:
-0.4805
ネットキャッシュフロー:
$-13.62M
1週間 パフォーマンス:
-7.43%
1か月 パフォーマンス:
-13.68%
6か月 パフォーマンス:
-38.40%
1年 パフォーマンス:
-40.88%
1日の値動き範囲:
$4.80
$5.13
1週間の範囲:
$4.80
$5.50
52週間の値動き範囲:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.86 | 189.42M | 147.12M | -33.88M | -13.62M | -0.4805 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 開始されました | William Blair | Outperform |
| 2024-09-05 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | ダウングレード | Stephens | Overweight → Equal-Weight |
すべてを表示
Lifecore Biomedical Inc (LFCR) 最新ニュース
Form 13D/A LIFECORE BIOMEDICAL For: 2 July By Investing.com - Investing.com India
Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026 - TradingView
Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests - Stock Titan
[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \DE\ Amended Major Shareholder Report - Stock Titan
(LFCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations? - Yahoo Finance
Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)? - simplywall.st
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirt - The National Law Review
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Enterprise value to revenue forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Price to sales forward of Lifecore Biomedical, Inc. – SWB:LDE - TradingView
Price to book forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Price to sales forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR) - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biom - The National Law Review
Enterprise value to EBITDA forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Enterprise value to EBITDA forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Price to earnings forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE) - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR) - TradingView
LFCR Forecast — Price Target — Prediction for 2027 - TradingView
LDE Forecast — Price Target — Prediction for 2027 - TradingView
LFCR Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEnergy Earnings Report - dars.gov.et
How (LFCR) Movements Inform Risk Allocation Models - Stock Traders Daily
LFCR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin, Stock Edges HigherAnnual Report - dars.gov.et
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lifecore Biomedical Inc (LFCR) Institutional Confidence - TradingKey
Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lifecore Biomedical Inc (LFCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lifecore Biomedical Inc (LFCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lifecore Biomedical signs manufacturing deal for neurology product By Investing.com - Investing.com Nigeria
Lifecore Biomedical signs manufacturing deal for neurology product - Investing.com
Lifecore Biomedical Signs Agreement for Tech Transfer and Commercial Production of Neurological Injectable Product - Quiver Quantitative
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company - GlobeNewswire
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentPreliminary Results - newsline.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook - Yahoo Finance
Trading Systems Reacting to (LFCR) Volatility - Stock Traders Daily
Lifecore Biomedical (LFCR) director awarded 25,907 RSUs - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock award - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907 restricted stock units - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock unit grant - Stock Titan
Lifecore Shareholders Approve New 2026 Stock Incentive Plan - TipRanks
Lifecore Biomedical (NASDAQ: LFCR) wins approval for 2026 stock plan - Stock Titan
LFCR Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite WeaknessAnnual Financial Report - newsline.com
Lifecore Biomedical Signs Tech Transfer Agreement for Ophthalmic - Contract Pharma
Lifecore Biomedical Inc (LFCR) 財務データ
収益
当期純利益
現金流量
EPS
0.17%
1.98%
大文字化:
|
ボリューム (24 時間):